Advertisement
Screener

Humacyte, Inc. (HUMA) Graph

HUMA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $406.00K; Revenue including tax (m); Cost of revenue $1.23M; Research and development $18.14M.
  • 2026-03-31: Revenue $495.00K; Revenue including tax (m); Cost of revenue $2.04M; Research and development $19.46M.
  • 2025-12-31: Revenue $467.00K*; Revenue including tax (m); Cost of revenue $9.08M*; Research and development $14.61M*.
  • 2025-09-30: Revenue $753.00K; Revenue including tax (m); Cost of revenue $260.00K; Research and development $17.27M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

HUMA revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product AndService Other$0.00Product$406.00KRevenue$406.00KCost of revenue$1.23MOperating income-$27.00MResearch & development$18.14MIncome tax$0.00Net income-$36.80M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$406.00K(m)$1.23M$18.14M(m)(m)$0.00-$36.80M
2026-03-31$495.00K(m)$2.04M$19.46M(m)(m)$0.00-$17.62M
2025-12-31$467.00K*(m)$9.08M*$14.61M*(m)(m)$0.00*-$24.80M*
2025-09-30$753.00K(m)$260.00K$17.27M$7.61M(m)$0.00-$17.51M
2025-06-30$301.00K(m)$213.00K$22.01M$7.81M(m)$0.00-$37.66M
2025-03-31$517.00K(m)$147.00K$15.42M$8.14M(m)$0.00$39.14M
2024-12-31(m)(m)(m)(m)(m)$28.09M*(m)(m)
2024-09-30$0.00(m)$0.00$22.93M$7.31M$30.23M$0.00-$39.20M
2024-06-30$0.00(m)$0.00$23.75M$5.75M$29.50M$0.00-$56.66M
2024-03-31$0.00(m)$0.00$21.26M$5.31M$26.58M$0.00-$31.90M
2023-09-30(m)(m)(m)$18.55M(m)$24.62M$0.00-$26.00M
2023-06-30(m)(m)(m)$20.54M(m)$26.73M$0.00-$22.71M
2023-03-31(m)(m)(m)$17.28M(m)$22.51M$0.00-$36.97M
2022-09-30(m)(m)(m)$17.34M(m)$23.52M$0.00-$25.28M
2022-06-30(m)(m)(m)$14.65M(m)$19.83M$0.00$36.87M
2022-03-31(m)(m)(m)$16.31M(m)$22.00M$0.00-$19.83M
2021-09-30(m)$241.00K(m)$15.39M(m)$20.78M$0.00-$31.56M
2021-06-30(m)(m)(m)$14.57M(m)$19.96M(m)-$17.20M
2021-03-31(m)(m)(m)$15.14M(m)$19.92M$0.00-$20.30M
2020-09-30(m)$914.00K(m)$14.69M(m)$18.13M(m)-$17.76M
2020-06-30(m)(m)(m)(m)(m)(m)(m)-$14.88M
2020-03-31(m)(m)(m)(m)(m)(m)(m)-$17.67M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$901.00K$3.27M$37.61M(m)(m)$0.00-$54.42M
2025-06-30$818.00K$360.00K$37.42M$15.95M(m)$0.00$1.48M
2024-06-30$0.00$0.00$45.02M$11.06M$56.08M$0.00-$88.56M
2023-06-30(m)(m)$37.82M(m)$49.24M$0.00-$59.67M
2022-06-30(m)(m)$30.97M(m)$41.83M$0.00$17.04M
2021-06-30(m)(m)$29.70M(m)$39.88M$0.00-$37.50M
2020-12-31(m)(m)(m)(m)(m)(m)$1.42M

Revenue and expense 9 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$1.57M(m)$620.00K$54.70M$23.55M(m)$0.00-$16.03M
2024-09-30$0.00(m)$0.00$67.94M$18.37M$86.31M$0.00-$127.76M
2023-09-30(m)(m)(m)$56.37M(m)$73.86M$0.00-$85.67M
2022-09-30(m)(m)(m)$48.30M(m)$65.35M$0.00-$8.24M
2021-09-30(m)$1.09M(m)$45.09M(m)$60.67M$0.00-$69.06M
2020-09-30(m)$1.37M(m)$40.88M(m)$50.30M(m)-$50.31M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$2.04M$9.70M$69.30M(m)$0.00-$40.83M
2024-12-31$0.00$0.00$88.60M$114.40M$0.00-$148.70M
2023-12-31(m)(m)$76.55M$100.05M$0.00-$110.78M
2022-12-31(m)(m)$63.26M$86.14M$0.00-$11.96M
2021-12-31(m)(m)$61.34M$82.47M$0.00-$26.48M
2020-12-31(m)(m)$54.08M$66.09M$0.00-$66.52M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63